Clinical inertia in the management of Type 2 diabetes metabolic risk factors

Diabetic Medicine

Volumn 21, Issue 2, 2004, Pages 150-155

  Grant, R W ^a   Cagliero, E ^a   Dubey, A K ^a   Gildesgame, C ^a   Chueh, H C ^a   Barry, M J ^a   Singer, D E ^a   Nathan, D M ^a   Meigs, J B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Hyperlipidaemia; Hypertension; Physician practice patterns; Practice guidelines

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC DIET; EXERCISE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK FACTOR; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 1242314755     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01095.x     Document Type: Article

References (25)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
2. American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation 1999; 100: 1132-3.
3. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
4. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
5. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
6. American Diabetes Association. Clinical practice recommendations 2001 Diabetes Care 2001; 24: S1-133.
7. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002; 136: 565-74.
8. Pringle M, Stewart-Evans C, Coupland C, Williams I, Allison S, Sterland J. Influences on control in diabetes mellitus, patient, doctor, practice, or delivery of care? BMJ 1993; 306: 630-34.
9. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 2000; 93: 369-74.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
11. Nathan DM, Singer DE, Godine JE, Harrington CH, Perlmuter LC. Retinopathy in older type II diabetics. Association with glucose control. Diabetes 1986; 35: 797-801.
12. Alexander M, Tekawa I, Hunkeler E, Fireman B, Rowell R, Selby JV et al. Evaluating hypertension control in a managed care setting. Arch Intern Med 1999; 159: 2673-7.
13. Criqui MH, Frankville DD, Barrett-Connor E, Klauber MR, Holdbrook MJ, Turner JD. Change and correlates of change in high-and low-density lipoprotein cholesterol after six years: a prospective study. Am J Epidemiol 1983; 118: 52-9.
14. Nathan DM. Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. Clin Chem 1981; 27: 1261-63.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
16. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipid lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. American Diabetes Association. Clinical practice recommendations 1997. Diabetes Care 1997; 20: S1-70.
19. Adult Treatment Panel II (NCEP). Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993; 269: 3015-23.
20. Choice of lipid-regulating drugs. Med Letter Drugs Therapeutics 2001; 43: 43-8.
21. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrika 1986; 42: 121-30.
22. SAS Institute I. SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute Inc, 1997.
23. Phillips LS, Branch WT, Cook CB, Doyle JP, el-Kebbi IM, Gallina DL et al. Clinical inertia. Ann Intern Med 2001; 135: 825-34.
24. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
25. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 11: 633-42.